How big is Repligen Corp.?

As of Jun 18, Repligen Corp. has a market capitalization of $6.8 billion, with net sales of $650.43 million and a net profit of -$22.98 million over the latest four quarters.

Market Cap: As of Jun 18, Repligen Corp. has a market capitalization of 6,798.72 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Repligen Corp. reported net sales of 650.43 million and a net profit of -22.98 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 1,972.72 million and total assets of 2,829.67 million.

What does Repligen Corp. do?

Repligen Corporation is a mid-cap bioprocessing company that develops and manufactures products to enhance biological drug manufacturing. As of March 2025, it reported net sales of $169 million and a net profit of $6 million.

Overview: <BR>Repligen Corporation is a bioprocessing company focused on the development, manufacture, and commercialization of products that enhance the biological drug manufacturing process, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 169 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 6,798.72 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 210.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.08 <BR>Return on Equity: 1.73% <BR>Price to Book: 3.42<BR><BR>Contact Details: <BR>Address: 41 Seyon St Bldg 1 Ste 100, WALTHAM MA: 02453-8348 <BR>Tel: 1 781 4499560 <BR>Website: https://www.repligen.com/

Should I buy, sell or hold Repligen Corp.?

Who are in the management team of Repligen Corp.?

As of March 2022, the management team of Repligen Corp. includes Independent Chairperson Ms. Karen Dawes, President and CEO Mr. Anthony Hunt, and Directors Ms. Carrie Eglinton, Mr. Nicolas Barthelemy, Mr. Rohin Mhatre, Mr. Glenn Muir, and Mr. Thomas Ryan. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Repligen Corp. includes the following individuals:<BR><BR>- Ms. Karen Dawes, who serves as the Independent Chairperson of the Board.<BR>- Mr. Anthony Hunt, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Carrie Eglinton, who is a Director.<BR>- Mr. Nicolas Barthelemy, who is an Independent Director.<BR>- Mr. Rohin Mhatre, who is also an Independent Director.<BR>- Mr. Glenn Muir, who serves as an Independent Director.<BR>- Mr. Thomas Ryan, who is another Independent Director. <BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is Repligen Corp. overvalued or undervalued?

As of November 12, 2024, Repligen Corp. is considered overvalued with a high P/E ratio of 210, an EV to EBITDA ratio of 56.65, and a year-to-date return of -13.59%, significantly underperforming the S&P 500.

As of 12 November 2024, Repligen Corp. has moved from an expensive to a risky valuation grade. The company appears to be overvalued, given its high P/E ratio of 210, significantly above its peer average of 181.22, and an EV to EBITDA ratio of 56.65, which also exceeds the industry benchmarks. Additionally, the Price to Book Value stands at 3.63, indicating a premium over its book value compared to peers like Neurocrine Biosciences, which has a P/E of 37.08.<BR><BR>In terms of performance, Repligen Corp. has underperformed relative to the S&P 500, with a year-to-date return of -13.59% compared to the index's 12.22%. Over the past three years, the stock has declined by 43.80%, while the S&P 500 has gained 70.41%, reinforcing the notion that the stock is currently overvalued.

Is Repligen Corp. technically bullish or bearish?

As of October 31, 2025, Repligen Corp. shows a bullish technical trend with positive MACD and RSI indicators, but it has underperformed the S&P 500 with year-to-date and one-year returns of 2.08% and 6.00%, respectively.

As of 31 October 2025, the technical trend for Repligen Corp. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the overall bullish stance. The RSI is bullish on a monthly basis, while Bollinger Bands indicate bullish conditions for both weekly and monthly time frames. However, the KST shows a bearish signal on the monthly, which slightly tempers the bullish outlook. <BR><BR>In terms of performance, Repligen has underperformed the S&P 500 across multiple periods, with a year-to-date return of 2.08% compared to the S&P 500's 16.30%, and a one-year return of 6.00% versus 19.89%. This suggests that while the technical indicators are currently bullish, the stock's performance relative to the benchmark remains weak.